10-Q quarterly report · filed Nov 4, 2026

LIFECORE BIOMEDICAL, INC. DE (LFCR) Q3 2026 10-Q Quarterly Report

Short answer

LIFECORE BIOMEDICAL, INC. DE (LFCR) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $25M with net income of −$40M.

Q3 2026 key financials · XBRL

Revenue
$25M
−25.9% QoQ
Net income
−$40M
−551.1% QoQ
Operating margin
-3.5%
Gross margin
27.0%
EPS (diluted)
−$1.09
−505.6% QoQ

Source: XBRL data from the LIFECORE BIOMEDICAL, INC. DE (LFCR) Q3 2026 10-Q on SEC EDGAR. USD.

LIFECORE BIOMEDICAL, INC. DE Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $25.3M, down 19% YoY from $31.1M
  • Gross margin 27.0% vs 25.0% YoY, gross profit $6.8M vs $7.8M
  • CDMO largest segment at $17.8M, down 18%; HA manufacturing weakest decline, down 19% to $7.5M
  • Cash $23.0M, operating cash flow $9.5M, revolving facility undrawn with $15.0M available
  • Outlook: liquidity sufficient for at least 12 months, Series A redemption obligation $51.1M due December 28, 2026

Risk Factors

  • New merger risk: closing depends on HSR Act clearance, with the waiting period scheduled to expire November 9, 2026
  • Most material update: Alcon relationship risk, Alcon represented 52% of nine-month revenue and must maintain specified agreements
  • Regulatory risk: additional governmental approval conditions could delay or prevent closing, or impose costs and operating limitations
  • Operational risk: merger uncertainty could disrupt CDMO customer relationships and key personnel retention
  • Financial risk: termination could require a $9,957,716 fee and leave debt maturing May 22, 2029

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other LIFECORE BIOMEDICAL, INC. DE quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.